Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis

Table 3 Association between chemoimmunotherapy and overall survival according to histology and sex

Multivariable Analysis
	Adenocarcinoma (n = 8256)	Squamous Cell Carcinoma (n = 2263)
	HR_adj^a (95% CI)	HR_adj^a (95% CI)
Chemoimmunotherapy Yes vs. No, Males	0.82 (0.75–0.90)	0.73 (0.58–0.91)
Chemoimmunotherapy Yes vs. No, Females	0.85 (0.77–0.94)	1.03 (0.76–1.38)
Immunotherapy*Sex	p = 0.6496	p = 0.0710
Propensity Matched Analysis^a
	Adenocarcinoma (n = 2958, 1479 pairs)	Squamous Cell Carcinoma (n = 276; 138 pairs)
	HR (95% CI)	HR (95% CI)
Chemoimmunotherapy Yes vs. No, Males	0.79 (0.70–088)	0.86 (0.61–1.21)
Chemoimmunotherapy Yes vs. No, Females	0.85 (0.74–0.96)	0.97 (0.62–1.53)
Immunotherapy*Sex	p = 0.4347	p = 0.6760

^aadjusted for/propensity matched on sex, age at diagnosis, histology (adenocarcinoma, squamous, large cell or other), race (white, Black or Asian/other), Charlson-Deyo comorbidity index, receipt of palliative radiation, year of diagnosis, insurance status (uninsured, privately insured, publically insured, unknown), and median household income for patient’s area of residence (< $38,000, $38,000–$47,999, $48,000–$62,999, >$63,000), * interaction effect
Abbreviations: HR Hazard Ratio, CI Confidence Interval

ISSN: 1471-2407